HIND Vyome Holdings, Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1427570 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-55.6%
TTM net income YoY59.8%
TTM EPS YoY100.2%
Revenue 3-yr CAGR-75.0%
Net income 3-yr CAGR—
Margins
Gross margin50.4%
Operating margin-2,853.6%
Net margin-2,455.6%
FCF margin—
EBITDA margin-2,846.7%
Returns
ROE-95.7%
ROA-48.0%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets24.0%
Debt / equity0.00x
Current ratio3.68x
Interest coverage-229.34x
Cash quality & payout
Operating cash flow / net income1.18x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $319,714 | $256,944 |
| Cost of revenue | $100,943 | $61,974 |
| Gross profit | $218,771 | $194,970 |
| R&D expense | $588,258 | $285,391 |
| SG&A expense | $2.37M | $898,572 |
| Operating income | -$10.45M | -$1.01M |
| Interest expense | $146,641 | $206,004 |
| Pretax income | — | -$7.09M |
| Income tax | — | $39,000 |
| Net income | -$10.26M | -$1.45M |
| EBITDA | -$10.44M | -$988,993 |
| EPS (basic) | -4.86 | -6,001.39 |
| EPS (diluted) | -4.86 | -6,001.39 |
| Weighted avg. shares (diluted) | 2.16M | 241 |
| Balance sheet | ||
| Cash & equivalents | $4.98M | $101,904 |
| Receivables | $325 | $2,294 |
| Inventory | — | $2.46M |
| Current assets | $5.44M | $302,046 |
| PP&E, net | $46,393 | $59,179 |
| Intangibles | $314,191 | $314,191 |
| Total assets | $6.50M | $1.38M |
| Current liabilities | $2.74M | $5.74M |
| Short-term debt | — | $811,000 |
| Total liabilities | $2.74M | $5.77M |
| Shareholders' equity | $2.44M | -$4.39M |
| Shares outstanding | 5.92M | 0 |
| Cash flow statement | ||
| Operating cash flow | -$3.75M | -$614,136 |
| Investing cash flow | — | $315 |
| Financing cash flow | $8.65M | $697,951 |
| Depreciation & amortization | $11,985 | $17,347 |
| Stock-based compensation | $577,128 | $184,000 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.